Related Experiment Videos
Cancer therapy utilizing an adenoviral vector expressing only E1A.
Andrew V Hubberstey1, Marta Pavliv, Robin J Parks
1Department of Biological Sciences, University of Windsor, Windsor, Ontario, Canada.
Cancer Gene Therapy
|April 18, 2002
Summary
Helper-dependent adenovirus vectors (hdAds) deliver early region 1A (E1A) proteins to cancer cells, reducing tumor growth and increasing sensitivity to chemotherapy. This approach shows promise for cancer therapy.
Area of Science:
- Oncology
- Gene Therapy
- Virology
Background:
- Human adenovirus type 5 (Ad5) early region 1A (E1A) proteins exhibit antitumor effects by reprogramming oncogenic signaling pathways.
- Previous studies demonstrated E1A's therapeutic potential in animal models, leading to clinical trials using liposome-based delivery.
Purpose of the Study:
- To develop an efficient delivery system for E1A to tumors.
- To evaluate the antitumor efficacy of a novel helper-dependent adenovirus vector encoding E1A (hdAd-E1A).
Main Methods:
- Construction of a helper-dependent adenovirus vector (hdAd-E1A) expressing only E1A.
- Infection of A549 human lung adenocarcinoma cells with hdAd-E1A.
- Assessment of cell proliferation, colony formation, apoptosis induction, and chemosensitivity.
Main Results:
- hdAd-E1A mediated high-level E1A expression in A549 cells.
- E1A expression significantly reduced A549 cell proliferation and abolished colony formation in soft agarose.
- E1A induction promoted apoptosis under serum-depleted conditions and increased cisplatin sensitivity by approximately 10-fold.
Conclusions:
- Helper-dependent adenovirus vectors provide an effective method for delivering E1A to cancer cells.
- E1A delivery via hdAd reduces cellular tumorigenic potential and enhances sensitivity to anticancer drugs.